Magrolimab
As of the edition of 20 October 2026, Magrolimab is an antibody: in active development; acts on CD47.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 36, 25 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Digestive system; Urinary and reproductive; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 companies on route A because of this drug.
Companies on route A for this drug
In the product4 companies are on route A because of Magrolimab.
See the 4 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD47 | Leukocyte surface antigen CD47 | Q08722 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 15 | 7 | 2 | 6 |
| Phase 2 | 17 | 1 | 0 | 16 |
| Phase 3 | 3 | 0 | 0 | 3 |
| All trials | 36 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Acerta Pharma | Lead sponsor of trials | 2018 to now |
| Roche | Lead sponsor of trials | 2019 to now |
| Ono Pharmaceutical | Lead sponsor of trials | 2020 to now |
| Otsuka | Lead sponsor of trials | 2023 to now |
| Novartis | Lead sponsor of trials | 2024 to now |
| Gilead Sciences | Lead sponsor of trials |